Prophylactic salpingectomy with delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in BRCA1/2 mutation carriers: women's point of view.
Journal
Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
17
5
2023
pubmed:
15
3
2023
entrez:
14
3
2023
Statut:
ppublish
Résumé
This study aimed to determine BRCA -mutation carrier women's interest and acceptability of participating in a study examining prophylactic salpingectomy with delayed oophorectomy (PSDO) as an alternative to the current recommendation for bilateral salpingo-oophorectomy for risk reduction. This is a cross-sectional questionnaire-based study. All women visiting the high-risk clinics for hereditary breast and ovarian cancer in a single tertiary medical center were asked to complete a questionnaire concerning the two-stage approach from October 2018 to December 2019. Before completing the questionnaire, detailed explanation was given by a senior physician regarding the procedure, related background, possible risks, and benefits. The study population included 293 women, of whom 183 (62.4%) were BRCA1 mutation carriers, 97 (33.1%) were BRCA2 mutation carriers, and 13 (4.4%) had unknown familial mutation. Risk-reducing surgery was completed in 160 (55.17%) of the women. First-degree and second-degree family history was reported in 166 (57.24%) and 52 (17.9%) of the women, respectively. Among women surveyed, more than half of the women (n = 66 [51%]) who had yet to undergo risk-reducing surgery reported interest in having PSDO. Similarly, among those who had already received prophylactic surgery, 64 (40%) also considered PSDO to be an acceptable alternative. Multivariate logistic regression analysis found family history of related malignancies to be the only independent factor associated with reduced interest in a study of PSDO (odds ratio, 0.15 [95% confidence interval, 0.29-0.77]; P = 0.02). Overall, BRCA -mutation carrier women indicated interest in PSDO risk-reducing surgery, taking into consideration the potential additional risk. These findings suggest that a clinical study exploring the equivalence of PSDO as alternative treatment is feasible.
Identifiants
pubmed: 36917763
doi: 10.1097/GME.0000000000002168
pii: 00042192-202305000-00004
doi:
Substances chimiques
BRCA1 protein, human
0
BRCA1 Protein
0
BRCA2 protein, human
0
BRCA2 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-479Informations de copyright
Copyright © 2023 by The North American Menopause Society.
Déclaration de conflit d'intérêts
Financial disclosure/conflicts of interest: None reported.
Références
Walker JL, Powell CB, Chen LM, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 2015;121:2108–2120. doi: 10.1002/cncr.29321
doi: 10.1002/cncr.29321
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80–87. doi: 10.1093/jnci/djn442
doi: 10.1093/jnci/djn442
Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223–229. doi: 10.1016/S1470-2045(06)70585-X
doi: 10.1016/S1470-2045(06)70585-X
Choi YH, Terry MB, Daly MB, et al. Association of risk-reducing salpingo-oophorectomy with breast cancer risk in women with BRCA1 and BRCA2 pathogenic variants. JAMA Oncol 2021;7:585–592. doi: 10.1001/jamaoncol.2020.7995
doi: 10.1001/jamaoncol.2020.7995
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–1130. doi: 10.1086/375033
doi: 10.1086/375033
Kaunitz AM, Kapoor E, Faubion S. Treatment of women after bilateral salpingo-oophorectomy performed prior to natural menopause. JAMA 2021;326:1429–1430. doi: 10.1001/jama.2021.3305
doi: 10.1001/jama.2021.3305
Chang H, Kamara D, Bresee C, Lester J, Cass I. Short-term impact of surgically induced menopause on cognitive function and wellbeing in women at high risk for ovarian cancer following risk-reducing bilateral salpingo-oophorectomy. Menopause 2020;28:354–359. doi: 10.1097/GME.0000000000001716
doi: 10.1097/GME.0000000000001716
Fakkert IE, Teixeira N, Abma EM, Slart R, Mourits M, de Bock GH. Bone mineral density and fractures after surgical menopause: systematic review and meta-analysis. BJOG 2017;124:1525–1535. doi: 10.1111/1471-0528.14703
doi: 10.1111/1471-0528.14703
Kingsberg SA, Larkin LC, Liu JH. Clinical effects of early or surgical menopause. Obstet Gynecol 2020;135:853–868. doi: 10.1097/AOG.0000000000003729
doi: 10.1097/AOG.0000000000003729
Chakrabarti R, Holloway D, Bruce D, Rymer J. The management of menopausal symptoms in women following treatment for cancer at a specialist menopause service. Post Reprod Health 2021;27:137–144. doi: 10.1177/20533691211000548
doi: 10.1177/20533691211000548
Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA -positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007;25:3985–3990. doi: 10.1200/JCO.2007.12.2622
doi: 10.1200/JCO.2007.12.2622
Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161–169. doi: 10.1097/01.pas.0000213335.40358.47
doi: 10.1097/01.pas.0000213335.40358.47
Ansink AC, Burger CW, Seynaeve C. Occult cancer in the fallopian tube in patients with a BRCA-1 germline mutation. Gynecol Oncol 2001;83:445. doi: 10.1006/gyno.2001.6290
doi: 10.1006/gyno.2001.6290
Bogani G, Tagliabue E, Signorelli M, et al. Assessing the risk of occult cancer and 30-day morbidity in women undergoing risk-reducing surgery: a prospective experience. J Minim Invasive Gynecol 2017;24:837–842. doi: 10.1016/j.jmig.2017.04.017
doi: 10.1016/j.jmig.2017.04.017
Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 2013;49:132–141. doi: 10.1016/j.ejca.2012.07.021
doi: 10.1016/j.ejca.2012.07.021
Kwon JS, Tinker A, Pansegrau G, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 2013;121:14–24. doi: 10.1097/aog.0b013e3182783c2f
doi: 10.1097/aog.0b013e3182783c2f
Lugo Santiago N, Smith E, Cox M, et al. Ovarian cancer after prophylactic salpingectomy in a patient with germline BRCA1 mutation. Obstet Gynecol 2020;135:1270–1274. doi: 10.1097/AOG.0000000000003864
doi: 10.1097/AOG.0000000000003864
Dullens B, de Putter R, Lambertini M, et al. Cancer surveillance in healthy carriers of germline pathogenic variants in BRCA1/2 : a review of secondary prevention guidelines. J Oncol 2020;2020:9873954. doi: 10.1155/2020/9873954
doi: 10.1155/2020/9873954
Finch A, Narod SA. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review. Maturitas 2011;70:261–265. doi: 10.1016/j.maturitas.2011.08.001
doi: 10.1016/j.maturitas.2011.08.001
Bommer C, Lupatsch J, Bürki N, Schwenkglenks M. Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA -mutation carriers in Switzerland. Eur J Health Econ 2022;23:807–821. doi: 10.1007/s10198-021-01396-9
doi: 10.1007/s10198-021-01396-9
Manchanda R, Gaba F, Talaulikar V, et al. Risk-reducing salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66. BJOG 2022;129:e16–e34. doi: 10.1111/1471-0528.16896
doi: 10.1111/1471-0528.16896
Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors — review of the literature. Pathol Oncol Res 2020;26:63–78. doi: 10.1007/s12253-018-00569-x
doi: 10.1007/s12253-018-00569-x
Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol 2014;133:283–286. doi: 10.1016/j.ygyno.2014.02.030
doi: 10.1016/j.ygyno.2014.02.030
Finch A, Metcalfe KA, Chiang J, et al. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 2013;22:212–219. doi: 10.1002/pon.2041
doi: 10.1002/pon.2041
Terra L, Hooning MJ, Heemskerk-Gerritsen BAM, et al. Long-term morbidity and health after early menopause due to oophorectomy in women at increased risk of ovarian cancer: protocol for a nationwide cross-sectional study with prospective follow-up (HARMOny Study). JMIR Res Protoc 2021;10:e24414. doi: 10.2196/24414
doi: 10.2196/24414
Boerner T, Long Roche K. Salpingectomy for the risk reduction of ovarian cancer: is it time for a salpingectomy-alone approach? J Minim Invasive Gynecol 2021;28:403–408. doi: 10.1016/j.jmig.2020.09.020
doi: 10.1016/j.jmig.2020.09.020